Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 892-906

  Banner, Katharine H ^a   Press, Neil J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Anti inflammatory; Bronchodilation; Chronic obstructive pulmonary disease; Phosphodiesterase; Synergistic

Indexed keywords

6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; 6 [4 (1,4 DIHYDRO 4 OXO 1 PYRIDYL)PHENYL] 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; AH 21 132; BENAFENTRINE; BY 343; CARDIAC GLYCOSIDE; CILOMILAST; GPD 1116; IC 542; LY 197055; MILRINONE; MOTAPIZONE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHTHALAZINONE; PLACEBO; PUMAFENTRINE; ROFLUMILAST; ROLIPRAM; RPL 554; RPL 565; SALBUTAMOL; SDZ ISQ 844; THEOPHYLLINE; TOLAFENTRINE; TREQUINSIN; UNCLASSIFIED DRUG; ZARDAVERINE;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ARTERITIS; ASTHMA; B LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DENDRITIC CELL; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIUM CELL; ENZYME INHIBITION; EOSINOPHIL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG EMPHYSEMA; LUNG FIBROBLAST; LUNG HEMODYNAMICS; MACROPHAGE; MESENTERY BLOOD VESSEL; MONOCYTE; NAUSEA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE; T LYMPHOCYTE; VASCULITIS; VERTIGO; VOMITING;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 70350345805     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00170.x     Document Type: Review

References (137)

1. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, et al. (2004). Non-redundant function of phosphodiesterase 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173: 7531-7538.
2. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP (1996). The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 119: 1255-1261.
3. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al. (2004). Differential expression of PDE4 cAMP phosphodi-esterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287: L332-L343.
4. Barnes PJ (1998). New therapies for chronic obstructive pulmonary disease. Thorax 53: 137-147.
5. Barnes PJ (2003). New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54: 113-129.
6. Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J, Gantner F et al. (1999). Specific CD3e association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J Immunol 162: 2016-2023.
7. Bayes M, Rabasseda X, Prous JR (2002). Gateways to clinical trials. Methods Find Exp Clin Pharmacol 24: 159-184.
8. Beavo JA, Brunton LL (2002). Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718.
9. Berends C, Dijkhuizen B, de Monchy JG, Dubois AE, Gerritsen J, Kauffman HF (1997). Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils by the type 4 selective PDE inhibitor, rolipram. Eur Respir J 10: 1000-1007.
10. Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T et al. (2004). Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol 68: 2229-2236.
11. Billington CK, LeJeune IR, Young KW, Hall IP (2008). A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 38: 1-7.
12. Bingham J, Sudarsanam S, Srinivasan S (2006). Profiling human phos-phodiesterase genes and splice isoforms. Biochem Biophys Res Commun 350: 25-32.
13. Bishop SP (1989). Animal models of vasculitis. Toxicol Pathol 17: 109-117.
14. Blanc PD, Iribarren C, Trupin L, Earnest G, Katz PP, Balmes J et al. (2009). Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 64: 6-12.
15. Blease K, Burke-Gaffney A, Hellewell PG (1998). Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124: 229-237. (Pubitemid 28210064)
16. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP (2006). The pharmacology of two novel long-acting phos-phodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2, 4,6-trimethylphenylimino)-3-(N-carbamoyl-2- aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido [6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 318: 840-848.
17. Brunnee T, Engelstatter R, Steinijans VW, Kunkel G (1992). Bronchod-ilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 5: 982-985.
18. Burgess JK, Oliver BG, Poniris MH, Ge Q, Boustany S, Cox N et al. (2006). A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 118: 649-657.
19. Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C (2008). Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol 154: 82-92.
20. Choi YH, Park S, Hockman S, Zmuda-Trzebiatowska E, Svennelid F, Haluzik M et al. (2006). Alterations in regulation of energy homeo-stasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest 116: 3240-3251.
21. Claveau D, Chen SL, O'Keefe S, Styhler A, Liu S, Huang Z et al. (2004). Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2- hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 310: 752-760.
22. Collins JJ, Elwell MR, Lamb JC, Manus AG, Heath JE, Makovec GT (1988). Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fundam Appl Toxicol 11: 472-484.
23. Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278: 5493.
24. Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM et al. (1999). A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 126: 1863-1871.
25. Dagues N, Pawlowski V, Sobry C, Hanton G, Borde F, Soler S et al. (2007). Investigation of the molecular mechanisms preceding PDE4-inhibitor-induced vasculopathy in rats: TIMP-1, a potential predictive biomarker. Toxicol Sci 100: 238-247.
26. Demedts IK, Bracke KR, Van Pottelberge G, Testelmans D, Verleden GM, Vermassen FE et al. (2007). Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 998-1005.
27. Denis D, Riendeau D (1999). Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Eur J Pharmacol 367: 343-350.
28. Dent G, White SR, Tenor H, Bodtke K, Schudt C, Leff AR et al. (1998). Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 11: 47-56.
29. Derian CK, Santulli RJ, Rao PE, Solomon HF, Barrett JA (1995). Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol 154: 308-317.
30. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P et al. (1998). Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158: 1277-1285.
31. Dietsch GN, DiPalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB et al. (2006). Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 34: 39-51.
32. Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA et al. (2008). Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J 31: 599-610.
33. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A et al. (2005). Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 60: 293-300.
34. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007). Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572: 12-22.
35. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S et al. (2003). Benzyl vinylogous amide substituted aryldihydropy-ridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg Med Chem Lett 13: 3983-3987.
36. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SR (1997). Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phos-phodiesterase inhibitors. J Pharmacol Exp Ther 282: 505-512.
37. Fernandes LB (1996). Phosphodiesterase inhibitors and endothelin as modulators of respiratory neurotransmission. Clin Exp Pharmacol Physiol 23: 980-982.
38. Fernandes LB, Ellis JL, Undem BJ (1994). Potentiation of nonadrener-gic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. Am J Respir Crit Care Med 150: 1384-1390.
39. Foster RW, Rakshi K, Carpenter JR, Small RC (1992). Trials of the bronchodilator activity of the isoenzyme-selective phosphodi-esterase inhibitor AH 21-132 in healthy volunteers during a metha-choline challenge test. Br J Clin Pharmacol 34: 527-534.
40. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S et al. (1999). Identification and function of cyclic nucleotide phos-phodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 20: 292-302.
41. Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A (1998). Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123: 1031-1038.
42. Gantner F, Schudt C, Wendel A, Hatzelmann A (1999). Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm Pharmacol Ther 12: 377-386.
43. Ghofrani HA, Olschewski H, Rose F, Schermuly R, Weissmann N, Schudt C et al. (2001). Prolongation of prostanoid inhalation-induced pulmonary vasodilation by concomitant PDE-3/4 inhibition in patients with sever pulmonary hypertension. Am J Respir Crit Care Med 163: A540.
44. Giembycz MA (2005). Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 326-333.
45. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ (1996). Identification of cyclic AMP phosphodiesterases 3,4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating prolif-eration and the biosynthesis of interleukin-2. Br J Pharmacol 118: 1945-1958.
46. Gosens R, Zaagsma J, Meurs H, Halayko AJ (2006). Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7: 73.
47. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R (2002). Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 300: 559-566.
48. Hansen G, Jin S, Umetsu DT, Conti M (2000). Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucle-otide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97: 6751-6756.
49. Hatzelmann A, Schudt C (2001). Anti-inflammatory and immuno-modulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279. (Pubitemid 32242587)
50. Hatzelmann A, Engelstaetter R, Morley J, Mazzoni L (1996). Enzymic and functional aspects of dual-selective PDE3/4 inhibitors. In Schudt C, Dent G, Rabc KF (eds) Phosphodiesterase Inhibitors, Academic Press: London, pp. 147-160.
51. Heystek HC, Thierry AC, Soulard P, Moulon C (2003). Phosphodi-esterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 15: 827-835.
52. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD et al. (2007). Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 176: 454-459.
53. Horikoshi S, Imai T, Idaira K, Adachi M, Okamoto M (1994). Effects of inhaled SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isoen-zyme type III/IV inhibitor, on airway responsiveness in beagles. Arerugi 43: 551-556.
54. Hoymann HG, Heinrich U, Beume R, Kilian U (1994). Comparative investigation of the effects of zardaverine and theophylline on pulmonary function in rats. Exp Lung Res 20: 235-250.
55. Ishiura Y, Fujimura M, Nobata K, Abo M, Oribe T, Myou S et al. (2005). Phosphodiesterase 3 inhibition and cough in elderly asthmatics. Cough 1: 11.
56. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H et al. (1996). Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 8: 575-581.
57. Jin SL, Conti M (2002). Induction of the cyclic nucleotide phosphodi-esterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99: 7628-7633.
58. Jones NA, Boswell-Smith V, Lever R, Page CP (2005). The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18: 93-101.
59. Joseph EC (2000). Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and D1 agonists. Toxicol Lett 112: 537-546.
60. Kelley TJ, al-Nakkash L, Drumm ML (1995). CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 13: 657-664.
61. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai SW, Chen SR et al. (2007). PI3Kg is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res 101: 400-408.
62. Kohyama T, Liu X, Wen FQ, Wang H, Kim HJ, Takizawa H et al. (2002). PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26: 694-701.
63. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeld C (2003). In vivo efficacy in airway disease models of N-(3,5-Dichloro-pyrid-4-yl)-[1-(4- flurobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phoshodiesterase 4 inhibitor for inhaled administration. JPET 307: 373-385.
64. Lagente V, Martin-Chouly C, Boichot E, Martins MA, Silva PM (2005). Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz 100: 131-136.
65. Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A et al. (2001). Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 133: 722-729.
66. Leclerc O, Lagente V, Planquois J-M, Berthelier C, Artola M, Eichholtz T et al. (2006). Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27: 1102-1109.
67. Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvery RD et al. (2005). Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123: 25-35.
68. LeJeune IR, Shepherd M, Van Heeke G, Houslay MD 7, Hall IP (2002). Cyclic AMP-dependent transcriptional up-regulation of phosphodi-estease 4D5 in human airway smooth muscle cells. J Biol Chem 277: 35980-53989.
69. Liu H, Maurice DH (1999). Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274: 10557-10565.
70. Liu S, Veilleux A, Young A, Zhang L, Kwok E, Laliberté F et al. (2005). Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther 314: 846-854.
71. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al. (2006). Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27: 397-412.
72. Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS et al. (2004). The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol 32: 295-308.
73. Maestrelli P, Saetta M, Mapp CE, Fabbri LM (2001). Remodelling in response to infection and injury, airway inflammation and hyper-secretion of mucus in smoking subjects with COPD. Am J Respir Crit Care Med 164: S76-S80.
74. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T et al. (2002). Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 1084-1091.
75. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M et al. (1999). Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128: 1393.
76. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V (2004). Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 75: 823-840.
77. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005). Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172: 848-853.
78. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S et al. (2004). Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 114: 196-205.
79. Méhats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M (2003). PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17: 1831-1841.
80. Millen J, MacLean MR, Houslay M (2006). Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol 85: 679-691.
81. Molnar-Kimber K, Yonno L, Heaslip R et al. (1993). Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39: C77-C79.
82. Mori H, Nose T, Ishitani K, Souma S, Kasagi S, Akiyoshi T et al. (2008). Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain. Am J Physiol Lung Cell Mol Physiol 294: L196-L204.
83. Movsesian MA, Alharethi R (2002). Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomy-opathy. Expert Opin Investig Drugs 11: 1529-1536.
84. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
85. Naline E, Qian Y, Advenier C, Raeburn D, Karlsson JA (1996). Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 118: 1939-1944.
86. Netherton SJ, Maurice DH (2005). Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67: 263-272.
87. Netherton SJ, Sutton JA, Wilson LS, Carter RL, Maurice DH (2007). Both protein kinase A and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. Circ Res 101: 768-776.
88. Nyska A, Herbert RA, Chan PC, Haseman JK, Hailey JR (1998). Theophylline-induced mesenteric periarteritis in F344/N rats. Arch Toxicol 72: 731-737.
89. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK (1997). Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 155: 852-857.
90. Parkkonen J, Hasala H, Moilanen E, Giembycz MA, Kankaanranta H (2008). Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol. Pulm Pharmacol Ther 21: 499-506.
91. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46: 798-825.
92. Peachell PT, Undem BJ, Schleimer RP, MacGlashan D, Lichtenstein L, Cieslinski LB et al. (1992). Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 148: 2503-2510.
93. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C (2007). Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 178: 4820-4831.
94. Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J et al. (2004). Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett 14: 2955-2958.
95. Pryzwansky KB, Madden VJ (2003). Type 4A cAMP-specific phosphodi-esterase is stored in granules of human neutrophils and eosinophils. Cell Tissue Res 312: 301-311.
96. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N et al. (2005). Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 6: 128.
97. Qian Y, Girard V, Martin CA, Molimard M, Advenier C (1994). Rolip-ram, but not siguazodan or zaprinast, inhibits the excitatory non-cholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 7: 306-310.
98. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK et al. (2003). Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168: 968-975.
99. Rabe KF (2006). Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation. Proc Am Thorac Soc 3: 641-644.
100. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H (1993). Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 264: L458-L464
101. Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P et al. (1995). Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 50: 360-365.
102. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Lali-berté F et al. (2002). Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052.
103. Rock EM, Benzaquen J, Limebeer CL, Parker LA (2009). Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav 91: 537-541.
104. Rogers DF (2005). The role of airway secretions in COPD: pathophysi-ology, epidemiology and pharmacotheraputic options. COPD 2: 341-353.
105. Ruben Z, Deslex P, Nash G, Redmond NI, Poncet M, Dodd DC (1989). Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 17: 145-152.
106. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A et al. (1993). Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 147: 301-306.
107. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A et al. (1994). Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150: 1646-1652.
108. Sanz MJ, Alvarez A, Piqueras L, Cerdá M, Issekutz AC, Lobb RR et al. (2002). Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P-and E-selectin downregulation. Br J Pharmacol 135: 1872-1881.
109. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullam-setti S, Weissmann N et al. (2004). Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108.
110. Schmidt DT, Watson N, Dent G, Rühlmann E, Branscheid D, Magnus-sen H et al. (2000). The effect of selective and non-selective phos-phodiesterase inhibitors on allergen-and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 131: 1607-1618.
111. Schudt C, Winder S, Eltze M, Kilian U, Beume R (1991). Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions Suppl 34 (New Drugs Asthma Ther): 379-402.
112. Schudt C, Tenor H, Loos U, Mallmann P, Szamel M, Resch K (1993). Effects of selective PDE inhibitors on activation of human macroph-ages and lymphocytes. Eur Respir J 6: 367S.
113. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Man-ganiello V (2001). Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66: 241-277.
114. Siuciak JA, McCarthy SA, Chapin DS, Martin AN (2008). Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 197: 115-126.
115. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y et al. (2000). Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59: 347-356.
116. Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J et al. (2007). Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 19: 1765-1771.
117. Suttorp N, Weber U, Welsch T, Schudt C (1993). Role of phosphodi-esterases in the regulation of endothelial permeability in vitro. J Clin Invest 91: 1421-1428.
118. Suttorp N, Ehreiser P, Hippenstiel S, Fuhrmann M, Krüll M, Tenor H et al. (1996). Hyperpermeability of pulmonary endothelial mono-layer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 174: 181-194. (Pubitemid 26107325)
119. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanoviv R, Schudt C et al. (1995). Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 25: 625-663.
120. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996). Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118: 1727-1735.
121. Tilley DG, Maurice DH (2005). Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function. Mol Pharmacol 68: 596-605.
122. Tirouvanziam R (2006). Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect 19: 609-614.
123. Trevethick M, Banner KH, Ballard S, Barnard A, Lewis A, Browne J et al. (2007a). UK-500 001, a potent selective inhibitor of phosphodi-esterase type 4 (PDE4) designed for inhaled delivery, inhibits TNF-a, MIP-1b and LTB4 release from native human blood cells. Am J Res Crit Care Med 175: A116.
124. Trevethick M, Philip J, Chaffe P, Sladen L, Cooper C, Nagendra R et al. (2007b). In vivo profile of intratracheally delivered phosphodi-esterase type 4 (PDE4) inhibitor UK-500 001-inhibits bronchocon-striction and inflammation. Am J Res Crit Care Med 175: A927.
125. Ukena D, Rentz K, Reiber C, Sybrecht GW (1995). Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med 89: 441-444.
126. Undem BJ, Meeker SN, Chen J (1994). Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J Pharmacol Exp Ther 271: 811-817.
127. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DWP et al. (1994). Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 270: 250-259.
128. Van der Mey M, Bommele KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ et al. (2003). Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 46: 2008-2016.
129. Vassallo R, Kroening PR, Parambil J, Kita H (2008). Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol Immunol 45: 3321-3329.
130. Verona Pharma website. (2008). Planned anti-asthma and hay fever treatment passes crucial tests. http://www.veronapharma.com.
131. Wang P, Wu P, Ohleth K, Egan R, Billah M (1999). Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56: 170-174.
132. Watt AP, Schock BC, Ennis M (2005). Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 4: 415-423.
133. Wright LC, Seybold J, Robichaud A, Adcock I, Barnes P (1998). Phos-phodiesterase expression in human epithelial cells. Am J Physiol 275: L694-L700.
134. Zaher C, Halbert R, Dubois R, George D, Nonikov D (2004). Smoking-related diseases: the importance of COPD. Int J Tuberc Lung Dis 8: 1423-1428.
135. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M et al. (2002). Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsy-chopharmacology 27: 587-595.
136. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L et al. (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33: 1611-1623.
137. Zhang KY, Ibrahim PN, Gillette S, Bollag G (2005). Phosphodiesterase 4 as a potential drug target. Expert Opin Ther Targets 9: 1283-1305.